周忠诚

博士 研究主管

个人简介

周忠诚，博士毕业于南开大学，2018-2023工作于广州市妇女儿童医疗中心临床基因检测中心， 2023-至今工作于广州市妇女儿童医疗中心 优生围产研究所。主持国家自然青年科学基金项目、广州市青年博士“启航”项目等。

研究领域

（1）基因组稳定性与干细胞、肿瘤
（2）新型冠状病毒：检测新冠病毒流行变异株的特性，开发针对冠状病毒的广谱/特异疫苗和策略
（3）开发、优化CRISPR技术研究细胞发育生物学和疾病相关机理

科研成果

主要科研成果（#共同第一作者, *通讯作者）如下：

1. Zhou Z, Wang L, Ge F, Gong P, Wang H, Wang F, Chen L, Liu L. Pold3 is required for genomic stability and telomere integrity in embryonic stem cells and meiosis. Nucleic Acids Res. 2018 Apr 20;46(7):3468-3486


2. Dan J, Zhou Z, Wang F, Wang H, Guo R, Keefe DL, Liu L. Zscan4 Contributes to Telomere Maintenance in Telomerase-Deficient Late Generation Mouse ESCs and Human ALT Cancer Cells. Cells. 2022 Jan 28;11(3):456. doi: 10.3390/cells11030456.


3. Zhou Z#, Du P#, Yu M, Baptista-Hon D, Miao M, Xiang P, Lau J, Li G, Zhang K. Assessment of infectivity and the impact on neutralizing activity of immune sera of the COVID-19 variant, CAL.20C. Signal Transduct Target Ther. 2021 Jul 27;6(1):285.


4. Li G#, Zhou Z#, Du P#, Zhan M#, Li N, Xiong X, Tang S, Man M, Basptista-Hon D, Lu L. Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant. Signal Transduct Target Ther. 2022. Jul 19; 7(1):243. doi:10.1038/s41392-022-01062-3


5. Du P, Li N, Xiong X, Tang S, Dai Q, Liu Z, Wang T, Gu X*, Zhou Z*. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity. J Med Virol. 2022 Sep; 94(9):4287-4293. doi:10.1002/jmv.27885.


6. Zhou Z#, Du P#, Li N#, Xiong X#, Tang S, Dai Q, Wang T, Yu M, Man M, Lam K, Basptista-Hon D, Tai W, Monteiro O, Ng W, Lee U, Liu Z, Zhang K, Li G. Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant. MedComm. 2022 May 11;3(2):e143.doi:10.1002/mco2.143.


7. Hong H#, Zhou Z#, Xiong X, Liu Z, Zheng X, Quan Q, Yu M. SARS-CoV-2 Delta (B.1.627.2) Spike protein adjuvanted with Alumn-3M-052 enhances antibody production and neutralization ability. Front Public Health. 2023 Jan 6;10:976686. doi: 10.3389/fpubh.2022.976686


8. Li G#, Zhou Z#, Du P#, Yu M, Li N, Xiong X, Huang H, Liu Z, Dai Q, Zhang C, Zhang E, Song H, Baptista-Hon D, Miao M, Lau J, Xiang P, Zhang K. The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera. Precis Clin Med. 2021 Jul 30: pbab016


9. Gu X#, Dai Q#, Du P#, Li N, Li J, Zeng S, Peng S, Tang S, Wang L, Zhou Z*. Pold4 is dispensable for mouse development, DNA replication and DNA repair. Gene. 2023 Jan 30;851:147029. Epub 2022 Nov 7. doi:10.1016/j.gene.2022.147029.

代表性论著：

1. Zhou Z, Wang L, Ge F, Gong P, Wang H, Wang F, Chen L, Liu L*. Pold3 is required for genomic stability and telomere integrity in embryonic stem cells and meiosis. Nucleic Acids Res. 2018 Apr 20;46(7):3468-3486. doi: 10.1093/nar/gky098.

2. Dan J, Zhou Z, Wang F, Wang H, Guo R, Keefe DL, Liu L*. Zscan4 Contributes to Telomere Maintenance in Telomerase-Deficient Late Generation Mouse ESCs and Human ALT Cancer Cells. Cells. 2022 Jan 28;11(3):456. doi: 10.3390/cells11030456.

3. Zhou Z^#, Du P^#, Yu M, Baptista-Hon D, Miao M, Xiang P, Lau J, Li G, Zhang K*. Assessment of infectivity and the impact on neutralizing activity of immune sera of the COVID-19 variant, CAL.20C. Signal Transduct Target Ther. 2021 Jul 27;6(1):285.

4. Li G^#, Zhou Z^#, Du P^#, Zhan M^#, Li N, Xiong X, Tang S, Man M, Basptista-Hon D, Lu L*. Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant. Signal Transduct Target Ther. 2022. Jul 19; 7(1):243. doi:10.1038/s41392-022-01062-3

5. Du P, Li N, Xiong X, Tang S, Dai Q, Liu Z, Wang T, Gu X*, Zhou Z*. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity. J Med Virol. 2022 Sep; 94(9):4287-4293. doi:10.1002/jmv.27885.

6. Zhou Z^#, Du P^#, Li N^#, Xiong X^#, Tang S, Dai Q, Wang T, Yu M, Man M, Lam K, Basptista-Hon D, Tai W, Monteiro O, Ng W, Lee U, Liu Z, Zhang K, Li G*. Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant. MedComm. 2022 May 11;3(2):e143.doi:10.1002/mco2.143.

7. Hong H^#, Zhou Z^#, Xiong X, Liu Z, Zheng X, Quan Q, Yu M*. SARS-CoV-2 Delta (B.1.627.2) Spike protein adjuvanted with Alumn-3M-052 enhances antibody production and neutralization ability. Front Public Health. 2023 Jan 6;10:976686. doi: 10.3389/fpubh.2022.976686

8. Li G^#, Zhou Z^#, Du P^#, Yu M, Li N, Xiong X, Huang H, Liu Z, Dai Q, Zhang C, Zhang E, Song H, Baptista-Hon D, Miao M, Lau J, Xiang P, Zhang K*. The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera. Precis Clin Med. 2021 Jul 30: pbab016. doi: 10.1093/pcmedi/pbab016